4D Molecular Therapeutics (NASDAQ:FDMT) said on Thursday that the U.S. FDA has granted the regenerative medicine advanced therapy (RMAT) status to 4D-150 as a treatment for diabetic macular edema.

Long-term follow-up of Phase 1 patients treated with 4D-150 indicated stable visual acuity and retinal thickness over two years. 4D-150 demonstrated safety and efficacy in the PRISM (wet AMD) and ...

The collaboration between Hokuyo and SiLC is advancing machine vision in factory automation, service robots, logistics and smart infrastructure through 4D LiDAR technology. OSAKA, Japan and ...